CollaCare
CollaCare, licence 80088470: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Collageniux Laboratories Corp
- NPN or DIN-HM
- 80088470
- Status
- Active licence
- Licence date
- 26 September 2018
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Magnésium Source : Hydroxyde de magnésium | 5.0 milligramme | 50,000 µg |
| Collagène hydrolysé Source : Poissons -Peau | 200.0 milligramme | Not calculated |
Non-medicinal ingredients
Glycolate d'amidon sodique, Stéarate de magnésium, Cellulose microcristalline, Hydroxypropylcellulose, Povidone
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 3.0 Comprimé ; maximum: 5.0 Comprimé | 2.0 Tous les jours |
Uses authorised in Canada
Helps to reduce joint pain associated with osteoarthritis. Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may help prevent bone loss/osteoporosis / may reduce the risk of developing osteoporosis (in peri- and postmenopausal women) (in later life). Helps in the development and maintenance of bones.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Some people may experience mild gastrointestinal disturbances such as diarrhoea, abdominal pain, heartburn, nausea and vomiting; in which case, discontinue use.
- Précautions et mises en garde
If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If symptoms worsen, consult a health care practitioner.
Source
Official Health Canada record, licence 80088470
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.